Edition:
United States

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

253.40SEK
8:24am EDT
Change (% chg)

-3.80kr (-1.48%)
Prev Close
257.20kr
Open
257.40kr
Day's High
258.20kr
Day's Low
251.00kr
Volume
28,929
Avg. Vol
105,833
52-wk High
290.00kr
52-wk Low
158.00kr

Chart for

About

Hansa Medical AB is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which... (more)

Overall

Beta: 1.92
Market Cap(Mil.): kr9,696.80
Shares Outstanding(Mil.): 37.88
Dividend: --
Yield (%): --

Financials

  HMED.ST Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -4.97 -- --
ROI: -38.33 -7.75 12.60
ROE: -38.64 -10.55 14.49

BRIEF-Hansa Medical Q1 Operating Loss Widens To SEK 46.6 Million

* Q1 OPERATING LOSS SEK 46.6 MILLION VERSUS LOSS SEK 44.8 MILLION YEAR AGO

Apr 25 2018

BRIEF-Hansa Medical Appoints Søren Tulstrup New President And CEO

* SØREN TULSTRUP APPOINTED NEW PRESIDENT AND CEO OF HANSA MEDICAL

Mar 20 2018

BRIEF-Hansa Medical Granted Orphan Drug Designation By FDA

* HANSA MEDICAL RECEIVES FDA ORPHAN DRUG DESIGNATION FOR IDES AND THE TREATMENT OF GUILLAIN-BARRÉ SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 16 2018

BRIEF-Hansa Medical AB Q4 Net Revenue Sek 1.0 ‍​ Million Versus Sek 0.5 Million Year Ago

* Q4 NET REVENUE SEK 1.0 ‍​ MILLION VERSUS SEK 0.5 MILLION YEAR AGO

Feb 14 2018

BRIEF-‍Hansa Medical's board has resolved on a directed share issue of SEK 545 mln​

* ‍HANSA MEDICAL'S BOARD OF DIRECTORS HAS RESOLVED ON A DIRECTED SHARE ISSUE OF SEK 545 MILLION​ Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​

* ‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​

Nov 29 2017

Earnings vs. Estimates